Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT04993690 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

A Study of LP-168 in Participants With Relapse or Refractory B-Cell Lymphoma

StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 3 months later Dec 31, 2026 → Mar 31, 2027
See other at-risk trials from Guangzhou Lupeng Pharmaceutical Company LTD.

Record History

  1. Primary completion pushed from Dec 31, 2026 to Mar 31, 2027 Completion pushed from Jun 30, 2027 to Sep 30, 2027v7 Show 1 more changeShow less
    • Completion pushed from Jun 30, 2027 to Sep 30, 2027
  2. Primary completion date: Dec 31, 2024 to Dec 31, 2026 Completion date: Jun 30, 2025 to Jun 30, 2027v6 Show 1 more changeShow less
    • Completion date: Jun 30, 2025 to Jun 30, 2027
  3. Primary completion date: Dec 31, 2023 to Dec 31, 2024 Enrollment target: 156 to 200 · Completion date: Jun 30, 2024 to Jun 30, 2025v5 Show 2 more changesShow less
    • Enrollment target: 156 to 200
    • Completion date: Jun 30, 2024 to Jun 30, 2025
  4. Primary completion date: Jul 30, 2023 to Dec 31, 2023 Completion date: Dec 31, 2023 to Jun 30, 2024v4 Show 1 more changeShow less
    • Completion date: Dec 31, 2023 to Jun 30, 2024
  5. Study sites: 1 to 3v3
  6. Eligibility criteria shortened, about 3 wordsv2 See this version in full on ClinicalTrials.gov ↗
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This is an open-label, multi-center Phase 1/2 study of oral LP-168 in patients with CLL/SLL and NHL who have failed or are intolerant to standard of care.
Trial Details
NCT Number NCT04993690
Lead Sponsor Guangzhou Lupeng Pharmaceutical Company LTD.
Conditions B-cell Lymphoma
Enrollment 200 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov